CIC
Cornercap Investment Counsel Portfolio holdings
AUM
$192M
1-Year Return
17.05%
This Quarter Return
-2.06%
1 Year Return
+17.05%
3 Year Return
+45.89%
5 Year Return
+105.96%
10 Year Return
+138.93%
AUM
$614M
AUM Growth
-$35.7M
(-5.5%)
Cap. Flow
-$20.7M
Cap. Flow
% of AUM
-3.37%
Top 10 Holdings %
Top 10 Hldgs %
8.77%
Holding
722
New
115
Increased
83
Reduced
345
Closed
120
Top Buys
| 1 |
Comcast
CMCSA
|
$3.16M |
| 2 |
Advanced Micro Devices
AMD
|
$2.26M |
| 3 |
Diamondback Energy
FANG
|
$2.23M |
| 4 |
PG&E
PCG
|
$2.17M |
| 5 |
Veeva Systems
VEEV
|
$2.05M |
Top Sells
| 1 |
Palo Alto Networks
PANW
|
$3.34M |
| 2 |
General Dynamics
GD
|
$2.93M |
| 3 |
Phillips 66
PSX
|
$2.76M |
| 4 |
Align Technology
ALGN
|
$2.65M |
| 5 |
L3Harris
LHX
|
$2.56M |
Sector Composition
| 1 | Financials | 18.85% |
| 2 | Technology | 17.63% |
| 3 | Healthcare | 12.62% |
| 4 | Industrials | 11.7% |
| 5 | Consumer Discretionary | 8.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
551
Nuvation Bio
NUVB
$1.33B
| $162K | 0.03% |
55,509
-62,548
| -53% | -$183K |
|
552
Generation Bio
GBIO
$40.3M
| $162K | 0.03% |
5,742
-1,675
| -23% | -$47.2K |
|
553
Monte Rosa Therapeutics
GLUE
$305M
| $157K | 0.03% |
41,917
-476
| -1% | -$1.78K |
|
554
Oric Pharmaceuticals
ORIC
$1.06B
| $154K | 0.03% |
+21,738
| New | +$154K |
|
555
Relay Therapeutics
RLAY
$710M
| $149K | 0.02% |
22,854
-234
| -1% | -$1.53K |
|
556
Prime Medicine
PRME
$663M
| $149K | 0.02% |
28,923
-318
| -1% | -$1.64K |
|
557
Allogene Therapeutics
ALLO
$255M
| $148K | 0.02% |
63,470
-633
| -1% | -$1.48K |
|
558
Foghorn Therapeutics
FHTX
$326M
| $147K | 0.02% |
25,567
-252
| -1% | -$1.45K |
|
|
RCM
559
DELISTED
R1 RCM Inc. Common Stock
RCM
| $146K | 0.02% |
11,615
-104,509
| -90% | -$1.31M |
|
560
Fate Therapeutics
FATE
$116M
| $143K | 0.02% |
43,472
-340
| -0.8% | -$1.12K |
|
561
Regenxbio
RGNX
$490M
| $142K | 0.02% |
12,168
-88
| -0.7% | -$1.03K |
|
562
Lyell Immunopharma
LYEL
$233M
| $140K | 0.02% |
4,814
-42
| -0.9% | -$1.22K |
|
563
Erasca
ERAS
$457M
| $136K | 0.02% |
57,504
-541
| -0.9% | -$1.28K |
|
564
TScan Therapeutics
TCRX
$108M
| $134K | 0.02% |
+22,940
| New | +$134K |
|
565
MeiraGTx Holdings
MGTX
$619M
| $134K | 0.02% |
31,716
-246
| -0.8% | -$1.04K |
|
566
Century Therapeutics
IPSC
$43.6M
| $130K | 0.02% |
51,015
-505
| -1% | -$1.29K |
|
567
C4 Therapeutics
CCCC
$194M
| $125K | 0.02% |
+27,136
| New | +$125K |
|
|
SAGE
568
DELISTED
Sage Therapeutics
SAGE
| $119K | 0.02% |
10,935
-113
| -1% | -$1.23K |
|
569
Alector
ALEC
$305M
| $110K | 0.02% |
24,319
-213
| -0.9% | -$967 |
|
570
Sutro Biopharma
STRO
$89.9M
| $104K | 0.02% |
35,360
-330
| -0.9% | -$967 |
|
571
CytomX Therapeutics
CTMX
$376M
| $98.3K | 0.02% |
80,591
-761
| -0.9% | -$928 |
|
572
Editas Medicine
EDIT
$248M
| $93K | 0.02% |
19,906
-254
| -1% | -$1.19K |
|
573
Invivyd
IVVD
$239M
| $85.5K | 0.01% |
+77,753
| New | +$85.5K |
|
574
BioAtla
BCAB
$31.5M
| $83K | 0.01% |
60,611
-589
| -1% | -$807 |
|
575
Verastem
VSTM
$663M
| $74.7K | 0.01% |
25,064
-210
| -0.8% | -$626 |
|